Welcome to our dedicated page for Dupont De Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DuPont de Nemours, Inc. filings document the regulatory disclosures of a Delaware specialty materials company with common stock listed on the New York Stock Exchange under DD. Its 8-K reports cover operating and financial results, Regulation FD disclosures, material events, board composition changes, corporate-governance matters and capital-structure disclosures.
DuPont proxy materials describe annual stockholder voting matters, director elections, governance practices, executive compensation and proposals affecting the company’s certificate of incorporation and common stock. Recent filings also document separation-related matters, including disclosures connected with the completed Qnity Electronics spin-off, as well as agreements and percentage calculations tied to the post-separation corporate structure.
DuPont de Nemours, Inc. reports higher profitability for the quarter ended March 31, 2026 while continuing a major portfolio reshaping. Net sales from continuing operations rose to $1.681 billion from $1.612 billion, and income from continuing operations increased to $150 million from $80 million.
Including discontinued operations, net income was $164 million, compared with a net loss of $(581) million a year earlier that was driven by large Aramids goodwill impairment and separation-related charges. Discontinued operations contributed $14 million of income versus a $(661) million loss in 2025.
On April 1, 2026 DuPont closed the Aramids business divestiture for gross consideration of $1.8 billion, receiving about $1.2 billion in cash, a $300 million note and a non‑controlling equity stake valued at $325 million. The Aramids and prior Electronics businesses are reported as discontinued operations. DuPont also launched a $80 million restructuring program in 2026 and is seeking shareholder approval for a reverse stock split at a 1‑for‑2 to 1‑for‑4 ratio, with a corresponding reduction in authorized shares. Environmental and PFAS‑related indemnification liabilities and reserves remain significant but are subject to cost‑sharing arrangements and proposed long‑term settlements.
DuPont de Nemours reported solid first quarter 2026 results and raised its full-year 2026 outlook. Net sales reached $1.681 billion, up 4% with 2% organic growth, while operating EBITDA rose to $414 million, a 15% increase and a 230 basis point margin expansion to 24.6%.
GAAP income from continuing operations grew to $150 million and GAAP EPS to $0.36, with adjusted EPS rising to $0.55, up 53% from the prior year. Cash provided by operating activities from continuing operations improved to $232 million, supporting transaction-adjusted free cash flow of $147 million.
The Healthcare & Water Technologies segment delivered 6% higher net sales and a 30.3% operating EBITDA margin; Diversified Industrials grew sales 3% with margins up to 22.9%. DuPont completed the $1.2 billion cash sale of its Aramids business plus a $300 million note and $325 million equity stake, and announced a planned $275 million accelerated share repurchase. The company now guides 2026 net sales of $7.155–$7.215 billion, operating EBITDA of $1.73–$1.76 billion, and adjusted EPS of $2.35–$2.40.
DuPont de Nemours Inc reported institutional ownership disclosure by Vanguard Capital Management. Vanguard Capital Management reports beneficial ownership of 30,793,971 shares of Common Stock, representing 7.51% of the class. The filing shows sole voting power of 4,200,077 shares and sole dispositive power of 30,793,971 shares.
DuPont de Nemours, Inc. reported that Luke Kissam resigned from its Board of Directors effective April 14, 2026. He is leaving in connection with his future appointment as Chief Executive Officer of Corteva, Inc. The company stated his departure is not due to any disagreement over operations, policies, or practices. Following his resignation, DuPont’s Board size was reduced from eleven to ten directors.
DuPont de Nemours, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on May 21, 2026 on four main items: electing 11 directors, approving executive pay on an advisory basis, ratifying the independent auditor, and approving a reverse stock split with a related reduction in authorized shares.
The Board highlights that 9 of 11 director nominees are independent, all directors are elected annually, and key committees are fully independent. The proxy details performance-based pay programs for executives, strong stock ownership and anti-hedging rules, and a 2025 short‑term incentive payout at just above target based on financial results.
DuPont de Nemours Inc: The Vanguard Group amended a Schedule 13G/A to report 0 shares beneficially owned of Common Stock, representing 0% of the class.
The filing explains that on January 12, 2026 Vanguard underwent an internal realignment and certain subsidiaries will report ownership separately, in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim as Head of Global Fund Administration on 03/26/2026.
DuPont de Nemours, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held online on May 21, 2026, with a record date of March 30, 2026. The Board recommends voting for all 11 director nominees and for approval of executive compensation, ratification of the independent auditor, and an amendment to effect a reverse stock split and reduce authorized shares.
The proxy highlights corporate governance practices, executive compensation design (including 2025 STIP and LTI decisions), committee responsibilities, and succession planning. The filing discloses 409,854,272 shares outstanding as of March 13, 2026, beneficial ownership schedules, non-employee director pay elements, and proposed Certificate of Amendment language for the reverse split.
DuPont de Nemours, Inc. plans a reverse stock split of its common stock, subject to stockholder approval, at a ratio between 1-for-2 and 1-for-4, with the exact ratio to be set later by the Board of Directors.
If implemented, the company will proportionally reduce authorized common shares. DuPont states the reverse split will not affect stockholder voting or other rights, business operations, or outstanding debt. The proposal will be voted on at the Annual Meeting of Stockholders on May 21, 2026, with a record date of March 30, 2026. The Board may delay or abandon the reverse split even if it is approved.
DuPont de Nemours, Inc. plans a reverse stock split of its common stock, subject to stockholder approval, at a ratio between 1-for-2 and 1-for-4, with the exact ratio to be set later by the Board of Directors.
If implemented, the company will proportionally reduce authorized common shares. DuPont states the reverse split will not affect stockholder voting or other rights, business operations, or outstanding debt. The proposal will be voted on at the Annual Meeting of Stockholders on May 21, 2026, with a record date of March 30, 2026. The Board may delay or abandon the reverse split even if it is approved.
DuPont de Nemours, Inc. reports that it expects to close the previously announced sale of its aramids business, which includes the Kevlar and Nomex product lines, to Arclin on April 1, 2026. All regulatory conditions required to complete the sale were satisfied as of March 10, 2026.
The company notes that statements about the timing and completion of the transaction are forward-looking and subject to various risks, including potential closing conditions, separation impacts and the future performance of the Arclin entity in which DuPont expects to hold a minority interest.